Preface |
| |
Authors: | Adi F Gazdar |
| |
Institution: | (1) Hamon Center for Therapeutic Oncology Research and Department of Pathology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593, USA |
| |
Abstract: | Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the USA and worldwide. Most patients present
with advanced disease, and treatment options for these patients are generally limited to platinum-based chemotherapy and a
few targeted therapies. Targeted agents currently in use for NSCLC inhibit oncogenic receptor tyrosine kinase pathways, such
as the epidermal growth factor receptor (EGFR) pathway. While current EGFR-targeted agents, including erlotinib and gefitinib,
may result in dramatic responses, they demonstrate efficacy in only a fraction of patients, and resistance to these agents
frequently develops. In order to select patients most likely to benefit from blockade of EGFR pathways, investigators have
focused on identifying molecular correlates of response to anti-EGFR therapy. New strategies to minimize the risk of resistance
to EGFR inhibition have been employed in the development of next-generation EGFR tyrosine kinase inhibitors, such as PF00299804
and BIBW 2992; these include irreversibility of target binding, inhibition of multiple EGFR family receptors, and/or simultaneous
inhibition of EGFR and other oncogenic pathways. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|